February 3, 2026
FIPNOPE, a global leader in veterinary antiviral solutions, has announced the official launch of GS-441524 Injection, a groundbreaking treatment for Feline Infectious Peritonitis (FIP), a deadly disease caused by mutated feline coronavirus. The new product is expected to provide veterinarians and cat owners worldwide with an effective tool to combat this challenging feline disease.
GS-441524, a nucleoside analog, works by blocking viral RNA replication, effectively stopping the virus from multiplying within the cat’s body. Clinical and laboratory studies have shown that this antiviral formulation is effective in managing both wet (effusive) and dry (non-effusive) FIP, offering significant improvement in cats under veterinary supervision.
"FIP is one of the most serious viral diseases affecting cats globally, often leaving owners with limited treatment options," said Italian animal rescue organization. "With the launch of GS-441524 Injection, we are providing a scientifically backed solution that helps cats recover while supporting veterinarians with a reliable, high-quality antiviral product."
Manufactured under strict quality control standards, GS-441524 Injection ensures high purity, consistent concentration, and stable formulation, making it suitable for global veterinary use. The product is administered via subcutaneous injection, with typical treatment periods ranging from 45 to 84 days, depending on the cat’s condition and response to therapy.
FIPNOPE continues to focus on veterinary innovation and global distribution, aiming to bring research-backed solutions to cat owners and veterinary professionals worldwide. The company’s launch of GS-441524 Injection underscores its commitment to advancing feline health and addressing critical unmet needs in veterinary care.
For more information about GS-441524 Injection and other veterinary solutions from FIPNOPE, visit www.fipnope.com
